-
公开(公告)号：US20210170018A1
公开(公告)日：2021-06-10
申请号：US17122627
申请日：2020-12-15
发明人： Michael Houghton , Abdolamir Landi , Carlos A. Guzman , Thomas Ebensen , Darren Hockman , John L. Law , Michael Logan
IPC分类号： A61K39/29 , C07K14/18 , C07K14/33 , C12N15/86 , C01F11/02 , C07D323/00 , C07K14/34 , A61K39/39 , A61P31/14 , A61K39/12 , A61P37/04 , C07K14/28 , C07K14/005 , A61K39/00
摘要： The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.
-
公开(公告)号：US12042536B2
公开(公告)日：2024-07-23
申请号：US18099035
申请日：2023-01-19
发明人： Michael Houghton , Abdolamir Landi , Carlos A. Guzman , Thomas Ebensen , Darren Hockman , John L. Law , Michael Logan
IPC分类号： A61K39/29 , A61K39/00 , A61K39/12 , A61K39/39 , A61P31/14 , A61P37/04 , C01F11/02 , C07D323/00 , C07K14/005 , C07K14/18 , C07K14/28 , C07K14/33 , C07K14/34 , C12N15/86
CPC分类号： A61K39/29 , A61K39/12 , A61K39/39 , A61P31/14 , A61P37/04 , C01F11/02 , C07D323/00 , C07K14/005 , C07K14/18 , C07K14/28 , C07K14/33 , C07K14/34 , C12N15/86 , A61K2039/543 , A61K2039/545 , A61K2039/55511 , A61K2039/55588 , C12N2770/24234
摘要： The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.
-
公开(公告)号：US11576968B2
公开(公告)日：2023-02-14
申请号：US17122627
申请日：2020-12-15
发明人： Michael Houghton , Abdolamir Landi , Carlos A. Guzman , Thomas Ebensen , Darren Hockman , John L. Law , Michael Logan
IPC分类号： A61K39/00 , A61K39/29 , C07K16/28 , A61K39/12 , C12N15/86 , A61P31/14 , A61P37/04 , C07K14/005 , A61K39/39 , C01F11/02 , C07D323/00 , C07K14/18 , C07K14/28 , C07K14/33 , C07K14/34
摘要： The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.
-
公开(公告)号：US20240058438A1
公开(公告)日：2024-02-22
申请号：US18099035
申请日：2023-01-19
发明人： Michael Houghton , Abdolamir Landi , Carlos A. Guzman , Thomas Ebensen , Darren Hockman , John L. Law , Michael Logan
IPC分类号： A61K39/29 , A61P31/14 , A61P37/04 , A61K39/12 , C07K14/005 , A61K39/39 , C01F11/02 , C07D323/00 , C07K14/18 , C07K14/28 , C07K14/33 , C07K14/34 , C12N15/86
CPC分类号： A61K39/29 , A61P31/14 , A61P37/04 , A61K39/12 , C07K14/005 , A61K39/39 , C01F11/02 , C07D323/00 , C07K14/18 , C07K14/28 , C07K14/33 , C07K14/34 , C12N15/86 , A61K2039/543
摘要： The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.
-
公开(公告)号：US10881726B2
公开(公告)日：2021-01-05
申请号：US16336732
申请日：2017-10-05
发明人： Michael Houghton , Abdolamir Landi , Carlos A. Guzman , Thomas Ebensen , Darren Hockman , John L. Law , Michael Logan
IPC分类号： A61K39/00 , A61K39/12 , A61K39/39 , A61K31/675 , A61K39/095 , A61K39/29 , A61P31/14 , A61P37/04 , C07K14/005 , C01F11/02 , C07D323/00 , C07K14/18 , C07K14/28 , C07K14/33 , C07K14/34 , C12N15/86
摘要： The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.
-
公开(公告)号：US11324818B2
公开(公告)日：2022-05-10
申请号：US16334683
申请日：2017-09-21
发明人： Michael Houghton , Abdolamir Landi , Michael Logan , John L. Law , Darren Hockman , Chao Chen
摘要： The present disclosure provides an immunogenic composition comprising: a) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; b) a T-cell epitope polypeptide comprising a T-cell epitope present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide. The present disclosure provides an immunogenic composition comprising: a) a polypeptide that comprises one or more T-cell epitopes present in an HCV protein other than E1 and E2; and b) a pharmaceutically acceptable excipient.
-
公开(公告)号：US20220105175A1
公开(公告)日：2022-04-07
申请号：US17511177
申请日：2021-10-26
发明人： Michael Houghton , Abdolamir Landi , Michael Logan , John L. Law , Darren Hockman , Chao Chen
摘要： The present disclosure provides an immunogenic composition comprising: a) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; b) a T-cell epitope polypeptide comprising a T-cell epitope present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide. The present disclosure provides an immunogenic composition comprising: a) a polypeptide that comprises one or more T-cell epitopes present in an HCV protein other than E1 and E2; and b) a pharmaceutically acceptable excipient.
-
公开(公告)号：US10881727B2
公开(公告)日：2021-01-05
申请号：US16374403
申请日：2019-04-03
IPC分类号： A61K39/00 , C07K16/28 , A61K39/21 , A61K48/00 , C12N15/86 , A61K39/29 , A61K39/12 , A61P37/04 , A61P31/14 , A61P31/04 , A61K39/295 , C12N15/861
摘要： The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV E1 polypeptide; 2) a variant HCV E1 polypeptide and an HCV E2 polypeptide; or 3) a variant HCV E1 polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV E1 polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV E1 polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes E1 and variant E2, E2 and variant E1, or variant E2 and variant E1. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.
-
公开(公告)号：US20180169219A1
公开(公告)日：2018-06-21
申请号：US15574427
申请日：2016-07-06
IPC分类号： A61K39/29 , A61K39/295 , C12N15/861 , A61P31/14 , A61P31/04 , A61P37/04
CPC分类号： A61K39/29 , A61K39/12 , A61K39/295 , A61K2039/55544 , A61P31/04 , A61P31/14 , A61P37/04 , C07K2319/00 , C12N15/861 , C12N2770/24234
摘要： The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV E1 polypeptide; 2) a variant HCV E1 polypeptide and an HCV E2 polypeptide; or 3) a variant HCV E1 polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV E1 polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV E1 polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes E1 and variant E2, E2 and variant E1, or variant E2 and variant E1. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.
-
公开(公告)号：US11186615B2
公开(公告)日：2021-11-30
申请号：US15763370
申请日：2016-10-07
发明人： Michael Houghton , Darren Hockman , John L. Law , Chao Chen , Michael Logan
IPC分类号： C07K14/005 , C12N15/62 , C12P21/02 , C07K1/22 , C07K19/00 , A61K39/12 , A61P31/14 , A61K39/29 , C12N7/00 , A61K39/00
摘要： The present disclosure provides affinity tagged heterodimeric polypeptides comprising a hepatitis C virus (HCV) E1 polypeptide and an HCV E2 polypeptide, where one or both of the E1 and E2 polypeptides comprises an affinity tag. The present disclosure provides a method of producing an affinity tagged E1/E2 heterodimer of the present disclosure. The present disclosure provides methods of producing untagged HCV E1/E2 heterodimers. The present disclosure provides HCV E1/E2 heterodimers, compositions comprising same, and methods of inducing an immune response to HCV.
-
-
-
-
-
-
-
-
-
搜索结果
23 条记录 (耗时 0.028 秒)
